Seattle biotech Atossa Therapeutics eyes acquisition of unnamed company
Atossa Therapeutics, a Seattle-based biotech company, paid $3 million for exclusive rights to negotiate an acquisition of an unnamed company in the pre-clinical stages of developing novel chimeric antigen receptor (CAR) T-cell therapies.
Atossa is looking to broaden its offerings, and the potential acquisition could aid the company to expand beyond its current leading program in breast cancer treatments.
“We view immunotherapy, including CAR T-cell therapy, as an area that could have a lot of appeal to our investors,” said Kyle Guse, chief financial officer at Atossa. “It’s something we’re very excited about and very optimistic about.”